Cyrus Karkaria, a visionary leader, has been the President of the Biotechnology division of Lupin since 2010. Currently based at Pune, he has over 27 years of rich industry experience in the field of Bio-pharmaceutical drug development while working with multi-national companies based out of US and India.
He has always held the strategic vision of making Lupin a global Bio-pharmaceutical powerhouse, by setting best in class industry benchmarks and global standards of development. Despite being a late entrant to the biosimilars segment, Lupin over the last 10 years under his invaluable guidance has gained significant momentum; thereby leading to streamlining of its vision, enrichment of pipeline products and strengthening of its globalization strategies. He helped create a strong foundation and devised strong in-house capabilities (vial to vial) across the drug development value chain. Under his leadership, regulatory and clinical strategies are formulated with a strong focus on harmonization of global regulatory guidelines and commercialization strategies are designed based on the complex regulatory, IP and competitive landscape. He has been instrumental in establishing a global footprint for Lupin Biotech, by adopting quality framework in line with stringent global norms, adapting quickly to the changing global landscape and reinventing business models by promoting a creative and flexible organization culture.
Before starting the stint at Lupin, he was Vice President at Celldex Therapeutics and CuraGen Corporation in New Haven, Connecticut, USA heading Operations and Biopharmaceutical Process Sciences.
He has also held positions at Biogen Idec and Scios and has been part of teams that have developed blockbusters in the field of neurology, immunology and oncology such as Avonex, Amevive and Tysabri (Biogen Idec). Such background experiences have helped create his expertise and proficiency in development and commercialization of biologic products.
He holds a Ph.D. in Biochemistry from the University of Maryland and was a post-doctoral researcher at the Harvard Medical School.